INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice
-
By
-
Sameer Sharma
-
Lixian Chen
-
Tianhao Zhou
-
Meenakshi Chawla
-
Anita Ganjoo
-
Shunichiro Okada
-
Salvatore Alesci
-
Krishnan Nandabalan
-
Heather Francis
-
June 9, 2026
-
Clinical Scorecard: The chymase inhibitor INVA8001 significantly reduces liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mouse models
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | |
| Care Setting | |
Key Highlights
- INVA8001 reduces chymase activity in Mdr2−/− mice
- Treatment leads to decreased mast cell accumulation and inflammation
- Histological damage and fibrosis are significantly reduced
- Chymase is implicated in the pathogenesis of PSC
- Potential therapeutic implications for other mast cell-driven diseases
Guideline-Based Recommendations
Diagnosis
Management
- Consider chymase inhibition as a therapeutic strategy for PSC
Monitoring & Follow-up
Risks
Patient & Prescribing Data
INVA8001 reduces liver inflammation and fibrosis
Clinical Best Practices
- Monitor mast cell markers in liver biopsies for disease severity
- Evaluate potential benefits of chymase inhibitors in clinical settings
Related Resources & Content
